Recurrent Prostate Cancer clinical trials

Explore recruiting recurrent prostate cancer clinical trials.

Recruiting recurrent prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Recurrent Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI) for the treatment of recurrent prostate cancer

Germany, Sweden

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

ADOPT; Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer - Pembro-SRT

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

(21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer

Spain, Denmark, Italy, Sweden, Finland, Germany +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort

Italy, Portugal, Finland, Sweden, Spain, Denmark +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Recurrent Prostate Cancer trials by city

Recurrent Prostate Cancer in Toronto Recurrent Prostate Cancer in Vancouver Recurrent Prostate Cancer in Montreal Recurrent Prostate Cancer in Calgary Recurrent Prostate Cancer in Edmonton Recurrent Prostate Cancer in Ottawa Recurrent Prostate Cancer in Winnipeg Recurrent Prostate Cancer in Quebec City Recurrent Prostate Cancer in Hamilton Recurrent Prostate Cancer in Kitchener Recurrent Prostate Cancer in London Recurrent Prostate Cancer in Halifax Recurrent Prostate Cancer in New York Recurrent Prostate Cancer in Los Angeles Recurrent Prostate Cancer in Chicago Recurrent Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease